GUMDROP : NCI 10-C-0114 A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Created by Marte, Jenn (NIH/NCI) [E], last modified by Channing Paller on Apr 14, 2012

Description:

At the present time, there are no drugs that have been proven to work in patients with papillary kidney cancer that has metastasized. This phase II study is designed to determine the effectiveness of the combination of bevacizumab and erlotinib in treating these patients. Participants will continue to receive treatment until disease progression, intolerable toxicity, or a better treatment option becomes available. The primary outcome measure is overall response rate (RECIST).

Link:

http://www.clinicaltrials.gov/ct2/show/NCT01130519

Site:

NCI

Principal Investigator:

Ramaprasad Srinivasan